Perffarmasp. z o.o.

Agents specialised in the sale of other particular products

KRS: NIP: REGON:

Overview

Status
Active
Registry date
2001-08-27
Share capital
84,000.00 PLN
Registered address
Królowej Marysieńki 13/11, 02-954 Warszawa, Poland
Electronic delivery address
AE:PL-15108-16249-AISEU-22

Financials

Revenue history (in k)

Filing timeliness

No financial statement for 2025 – the filing deadline has passed. 5 of 6 financial statements were filed late (the longest delay 1103 days for 2019).

  • 2025not filed
  • 202408/12/2025
  • 202326/06/2024
  • 202226/06/2024
  • 202123/10/2023
  • 202023/10/2023
Filed on timeDelayFiling deadline

Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.

Statistics

How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2024.

Division · Wholesale trade7,546 / 28,998
Top 26%
Voivodeship · Mazowieckie19,436 / 142,035
Top 14%
Country · Poland70,284 / 495,867
Top 14%

Results vs industry

Revenue
This companyUSD 2.52mMedianUSD 226.53kAverageUSD 2.28m
Net profit
This companyUSD 365.93kMedianUSD 6.25kAverageUSD 141.69k
Operating costs
This companyUSD 1.87mMedianUSD 187.76kAverageUSD 2.07m
Assets
This companyUSD 1.00mMedianUSD 163.28kAverageUSD 1.33m

National Health Fund (NFZ) contracts

Perffarma has been an NFZ healthcare provider since 2009. In 2010 it is performing 1 contract worth USD 0.00. All its contracts were worth USD 0.00 in total.

NFZ contract value by year (USD)

Type of careNFZ branchContractsValue in 2010
Supply of medical devices classified as orthopedic devices and assistive productsmazowieckie1USD 0.00

Trademarks

Perffarma holds 38 active trademarks registered with the Polish Patent Office. 3 marks have expired or were not registered. The first mark was filed in 2006.

MarkNumberClassesStatusProtected until
PROBIOVAGINAL(word)Z.5842875, 10Protected May 7, 2035
IZILAX(word)Z.5547145, 10Protected Apr 13, 2033
FASTILAX(word)Z.5430075, 10Protected May 13, 2032
PREGRAVID(word)Z.5416775Protected Apr 5, 2032
BaroX(word)Z.5062325Protected Oct 29, 2029
MarkProtected until
PROBIOVAGINAL(word)May 7, 2035
IZILAX(word)Apr 13, 2033
FASTILAX(word)May 13, 2032
PREGRAVID(word)Apr 5, 2032
BaroX(word)Oct 29, 2029

Authorized Representatives

Jacek Andrzej Korbeckiage 60 – Management Board Member
Hugues Julien Chomeaux – President of the Management Board
Mohamed Riadh Fazaa – Management Board Member

Manner of representation

Each member of the management board acting independently is authorized to make declarations and sign on behalf of the company.

Ownership

OwnerSharesShare valueStake
Hugues Julien Chomeaux
40$7,563.4833.3333%
Mohamed Riadh Fazaa
40$7,563.4833.3333%
40$7,563.4833.3333%

Beneficial owners

Person

Subsidiaries

NameStake
30%

Bank accounts

Registered as a VAT taxpayer on 2001-10-11.

Debt

No entries in the National Debtors Register (KRZ).

Public aid

PurposeGross amount
De minimis aid (in accordance with Commission Regulation No 1407/2013 or earlier)
$1,678
Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts
$126.6K

Competitors

Name
Midas Pharma Polskasp. z o.o.
SynektikS.A.
Energy Centersp. z o.o.
Sądkiewicz-Servicesp. k.
Symkomsp. z o.o.
Business Solutions & Supportsp. z o.o.
East Newssp. z o.o.
Cambridge Diagnostics (Polska)sp. z o.o.
En-Brokersp. z o.o.
Koperkowy Światsp. z o.o.

Change history

DateEvent
2011-04-26Share capital increase
2005-08-30Share capital increase
2005-08-30Name change
2001-08-27Entered in the register

FAQ

Last updated: 2026-04-01